We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

I Agree

You are here: Industry Insights > Emflaza

News List

PTC Therapeutics Receives FDA Approval for the Expansion of the Emflaza (deflazacort) Labeling to Include Patients 2-5 Years of Age drugs
June 11, 2019
PTC Therapeutics Receives FDA Approval for the Expansion of the Emflaza (deflazacort) Labeling to Include Patients 2-5 Years of Age.
Duchenne drug poised to cost $35,000 but with major catch pharmafiles
May 10, 2017
For those that have not followed the story, Emflaza was successfully taken through the FDA regulatory process by Marathon as the first new treatment for Duchenne muscular dystrophy.
US FDA approves Emflaza tablets to treat patients with DMD pharmaceutical-technology
February 14, 2017
The US Food and Drug Administration (FDA) has approved Emflaza (deflazacort) tablets and oral suspension to treat patients with Duchenne muscular dystrophy (DMD).
FDA Approves Emflaza drugs.com
February 10, 2017
FDA Approves Emflaza (deflazacort) to treat Duchenne Muscular Dystrophy